Screener
Evolent Health, Inc. EVH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Evolent Health, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Evolent Health, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:53 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628908-26-000086
FAQ
- What is Evolent Health, Inc.'s cash & equivalents?
- Evolent Health, Inc. (EVH) reported cash & equivalents of $115.7M in Q2 2026.
- How has Evolent Health, Inc.'s cash & equivalents changed year-over-year?
- Evolent Health, Inc.'s cash & equivalents decreased by 23.4% year-over-year, from $151M to $115.7M.
- What is the long-term trend for Evolent Health, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Evolent Health, Inc.'s cash & equivalents has grown at a -13.8% compound annual growth rate (CAGR), from $319M to $151.86M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Evolent Health, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude